Navigation Links
CuraGen to Present CR011-vcMMAE Data at ASCO
Date:5/28/2009

ragen.com following the presentations.

Conference Call Details and Dial-in Information

    Date:       Wednesday, June 3, 2009
    Time:       11:00 a.m. EDT
    Dial-in:    (877)-856-1956  (U.S. and Canada)
                (719)-325-4771  (international)

Webcast: Access available at http://www.curagen.com

About CR011-vcMMAE

CR011-vcMMAE is an antibody-drug conjugate (ADC) being developed by CuraGen that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CR011-vcMMAE targets and binds to GPNMB, a specific protein that is predominantly expressed on the surface of cancer cells, including melanoma, breast cancer and gliomas. Upon internalization into the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. CR011-vcMMAE is currently in two Phase II trials assessing the safety and efficacy in the treatment of melanoma and for the treatment of metastatic breast cancer, and in a Phase I trial to evaluate the safety and activity of alternate dosing schedules.

About Breast Cancer

Breast cancer is the most common cancer in women and a leading cause of death in the United States. According to the American Cancer Society, more than 180,000 women will be diagnosed with invasive breast cancer in 2009 with more than 40,000 deaths attributed to this disease. Despite recent advances in therapy, the median survival of patients with metastatic breast cancer is 2 to 3 years, while patients with "triple-nega
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)...   Continental Clinical Solutions (Continental) announced it is expanding its Baltimore ... volume in clinical studies and demand for unique patient populations.  ... ... ... ...
(Date:7/1/2015)... , July 1, 2015 OncoSec Medical Inc. ... cancer immunotherapies, today announced that CEO and President Punit ... of the Company,s listing to The Nasdaq Stock Market at ... MarketSite in New York City .   ... investors, and stakeholders, we are honored to open the Nasdaq ...
(Date:7/1/2015)... 2015 The global mHealth ... USD 49,119.2 million by 2020, according to a new ... expected to remain the dominant and fastest growing market ... 2012, and an estimated CAGR of 49.7% from 2014 ... , Browse full research report with TOC ...
Breaking Medicine Technology:Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 2Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 3Continental Clinical Solutions CEO Saleh Stevens Eyes Growth 4OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 2OncoSec Medical to Ring The Nasdaq Stock Market Opening Bell 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... Reportlinker.com announces that a new market ... Fetal Monitoring, Diagnostics and ... An overview of the ... tests. Analysis of market trends, with data ...
... -- Nutrastar International Inc. (OTCBB: NUIN; "Nutrastar" or the ... Traditional Chinese Medicine ("TCM") consumer products, today announced that ... conference call on Monday, May 16, 2011 at 8:00 ... the public pre-market on Monday, May 16, 2011. ...
Cached Medicine Technology:Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 2Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 3Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 4Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 5Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 6Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 7Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 8Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 9Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 10Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests 11Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 2Nutrastar Provides First Quarter 2011 Financial Results Release Date and Conference Call Details 3
(Date:7/1/2015)... Livonia, Mich. (PRWEB) , ... July 01, 2015 ... ... the transition of Catholic sponsorship complete, St. Joseph’s Health, located in Syracuse, N.Y., ... "With the closing today, we have gained an admirable and important partner committed ...
(Date:7/1/2015)... , ... July 01, 2015 , ... ... Biomedical Sciences at Georgia State University and a Georgia Research Alliance Eminent Scholar ... develop novel anti-inflammatory therapeutics against middle-ear infections. , The grant from the National ...
(Date:7/1/2015)... ... July 01, 2015 , ... Sir Fazle Hasan Abed, BRAC’s ... Prize today. Sir Fazle has been recognised for his outstanding contribution to enhancing the ... Ken Quinn, President of the World Food Prize Foundation, announced this year’s winner at ...
(Date:7/1/2015)... ... July 01, 2015 , ... The federal ... ( http://www.injurybeacon.com/levaquin/lawsuit/ ) has granted the Defendants’ Motion for Summary Judgment. According to ... on June 26th, the Court rejected the Plaintiff’s assertion that one manufacturer ...
(Date:7/1/2015)... New York, NY (PRWEB) , ... July 01, 2015 , ... ... around which DNA is wound, histones, remain constant in the brain, never changing after ... Sinai have discovered that histones are steadily replaced in brain cells throughout life – ...
Breaking Medicine News(10 mins):Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Institute for Biomedical Sciences Researcher Gets $1.6 Million to Develop Anti-Inflammatory Drug 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 2Health News:Levaquin Lawsuit Attorneys at Bernstein Liebhard LLP Comment on Decision to Grant Summary Judgment in Generic Drug Case 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4
... supports the findings of a landmark drug comparison study published ... outperformed other medications for high blood pressure. A scientific team ... at Houston reports the findings in the May 11 issue ... one in three adults in the United States has high ...
... On Sunday, May 17, traffic near the University ... temporarily suspended for the 27th annual Nordstrom Beat the Bridge ... Research Foundation. Montlake Closures , From 7:30 ... NE Pacific Street to 44th Avenue NE. 520 Ramp ...
... all made mistakes: bell bottoms, scrunchies and laying out in the ... to advances in skin care and advice from experts, we now ... According to the National Cancer Institute, there will be 1 ... 1,000 deaths. Skin cancer is the most common form of ...
... HHS Deputy Director of the Office on Women,s HealthWASHINGTON, May ... ), a unique web project that collects and shares ... fight against HIV/AIDS, today announced that it has posted its ... on Women,s Health at the U.S. Department of Health and ...
... Speaker Nancy Pelosi received an "Award of ... on future directions in the fight against HIV/AIDS. amfAR,s ... individuals in recognition of the vision, determination, and courage ... AIDS. Other 2009 awardees are Senator Edward Kennedy, Dr. ...
... and only oral antidiabetic fixed-dose combination medication approved ... OSAKA, Japan, May 13 Takeda Pharmaceutical Company ... America, Inc., today announced that the ... extended-release version of the combination medication ACTO plus ...
Cached Medicine News:Health News:New research confirms milestone study on blood pressure meds 2Health News:New research confirms milestone study on blood pressure meds 3Health News:Nordstrom Beat the Bridge to Beat Diabetes Run to Temporarily Suspend Traffic in University District on Sunday, May 17 2Health News:Get Sun Smart at the Spa 2Health News:Southern AIDS Living Quilt Posts 100th Video Patch During National Women's Health Week 2Health News:Pelosi Remarks at amfAR Conference on Future Directions in Fight Against HIV/AIDS 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 2Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 3Health News:FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes 4
... The ABL800 FLEX is a fully ... most advanced blood gas analyzer along ... gives you the freedom to focus ... FLEX provides features that are essential ...
Flatbed Agitator....
Flatbed Agitator....
... platelet agitators offer a wide range of ... the drawer storage platform to agitate smoothly, ... wear down and squeak. Sturdy, one-piece perforated ... air circulation for your platelets., ,i.Series platelet ...
Medicine Products: